Newsfeeds - Spark Newswire

1 minute read

South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters

Today, 12:58 PM

South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the country.

AZN

2 minute read

The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week

By Shanthi Rexaline

Today, 12:58 PM

Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year.

ABOS

5 minute read

58 Biggest Movers From Yesterday

By Lisa Levin

Today, 12:58 PM

Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.

ABOS

3 minute read

30 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 12:58 PM

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on Wednesday after the company priced its IPO at $6 per share.

ALGS

1 minute read

FDA
News

EU Drug Regulator Says It Will Proceed With Evaluating CureVac Clinical Data For COVID-19 Vaccine

By Benzinga Newsdesk

Today, 12:58 PM

-Reuters

CVAC

1 minute read

Curevac CEO Said Earlier on Thursday, Company Was in Talks With EU Regarding its Covid Vaccine; Said Aiming to Produce 200M to 300M Doses This Year

By Charles Gross

Today, 12:58 PM

-Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-says-speaking-eu-about-ideal-region-vaccine-use-2021-07-01/

CVAC

2 minute read

20 Stocks Moving in Thursday’s Pre-Market Session

By Lisa Levin

Today, 12:58 PM

Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434 Phase 2 clinical trial.

ADMP

3 minute read

A Peek Into The Markets: US Stock Futures Up Ahead Of Initial Jobless Claims Data

By Lisa Levin

Today, 12:58 PM

Pre-open movers

AYI

1 minute read

CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals

By Vandana Singh

Today, 12:58 PM

The German biotech company CureVac BV (NASDAQ:CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial…

BNTX

4 minute read

CureVac Reports Data From Phase 2b/3 Trial Of COVID-19 Vaccine; Showed Efficacy Of 53% Against Disease Of Any Severity, Efficacy Of 77% Against Moderate And Severe Disease, Full Protection Against Hospitalization Or Death

By Bill Haddad

Today, 12:58 PM

CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 · Unique pivotal study conducted in

CVAC